ADMA Biologics, Inc.
ADMA Biologics, Inc. (ADMA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ADMA · as of Jun 8, 2026
Key Statistics
Explore ADMA Biologics, Inc. Data
adma stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 90.0%
The ADMA analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $21.00, representing +163.49% upside from the current price of $7.97.
Competitors & Peers
adma competitorsADMA
ACAD
BLTE
CRNX
DYN
LGNDStock Performance
Full HistoryAbout ADMA Biologics, Inc.
ADMA Biologics, Inc. a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseas…
what is adma biologics, inc. · adma stock overview · adma biologics, inc. company profile · who is adma biologics, inc. ceo · adma NASDAQ · adma biologics, inc. headquarters · adma biologics, inc. business segments
About Stock Overview & Key Data
ADMA Biologics, Inc. (ADMA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 17, 2013. As of the latest trading session, ADMA stock price is $7.97, with a market capitalization of $1.8B. The stock has returned -61.81% over the past 12 months and -56.30% year-to-date.
According to 10 Wall Street analysts, the consensus rating for ADMA Biologics, Inc. stock is Buy, with an average 12-month price target of $21.00. In fiscal year 2025, ADMA Biologics, Inc. reported revenue of $510.2M and net income of $146.9M. For detailed data — including ADMA Biologics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, ADMA Biologics, Inc. (ADMA) stock price is $7.97. The stock is traded on NASDAQ under the ticker symbol ADMA. The 52-week range is $7.21 – $22.37.